Develops drugs for Alzheimer's disease, dry AMD, and Epidermolysis Bullosa.
Dec 2025Revenue $4.51M/yrExpenses $12.2M/yr
No trend
Figures by year
When will InMed Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $4.51M and expenses $12.2M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Jun 2025 | $4.94M | $13.6M | −$8.69M |
| Jun 2024 | $4.60M | $12.3M | −$7.67M |
| Jun 2023 | $4.14M | $12.1M | −$7.93M |
| Jun 2022 | $1.09M | $19.7M | −$18.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.